Cerebrospinal fluid neurofilament light chain levels: Marker of progression to generalized amyotrophic lateral sclerosis

European Journal of Neurology

Volumn 22, Issue 1, 2015, Pages 215-218

  Tortelli, R ^a   Copetti, M ^b   Ruggieri, M ^a   Cortese, R ^a   Capozzo, R ^a   Leo, A ^a   D'Errico, E ^a   Mastrapasqua, M ^a   Zoccolella, S ^a   Pellegrini, F ^b   Simone, I L ^a   Logroscino, G ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

ALS; Biomarkers; CSF

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT LIGHT CHAIN; UNCLASSIFIED DRUG; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HAZARD RATIO; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN LOCALIZATION; SYMPTOM; ADULT; AGED; MIDDLE AGED; PROGNOSIS; TIME;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; PROGNOSIS; TIME FACTORS;

EID: 84923083893     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12421     Document Type: Article

References (13)

1. Brettschneider J, Petzold A, Submuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006; 66: 852-856.
2. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen P. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007; 14: 1329-1333.
3. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009; 256: 615-619.
4. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011; 117: 528-537.
5. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012; 19: 1561-1567.
6. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009; 73: 805-811.
7. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994; 124(Suppl.): 96-107.
8. Chiò A, Mora G, Leone M, et al. (PARALS).Early symptom progression rate is related to ALS outcome. A prospective population-based study. Neurology 2002; 59: 99-103.
9. Korner S, Kollewe K, Fahlbusch M, et al. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve 2011; 43: 636-642.
10. Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 2007; 68: 1576-1582.
11. Fujimura-Kiyono C, Kimura F, Ishida S, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 1244-1249.
12. Brooks BR. The role of axonal transport in neurodegenerative disease spread: a meta-analysis of experimental and clinical poliomyelitis compares with amyotrophic lateral sclerosis. Can J Neurol Sci 1991; 18: 435-438.
13. Zoccolella S, Beghi E, Palagano G, et al. SLAP Registry.Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008; 79: 33-37.